<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284072</url>
  </required_header>
  <id_info>
    <org_study_id>S63631</org_study_id>
    <nct_id>NCT04284072</nct_id>
  </id_info>
  <brief_title>Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology</brief_title>
  <acronym>SeizeIT2</acronym>
  <official_title>A Multicenter Study to Examine Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Freiburg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Coimbra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Byteflies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helpilepsy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinically validate a biopotential and motion recording wearable device (Byteflies Sensor
      Dot) for detection of epileptic seizures in the epilepsy monitoring unit (EMU) and at home.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with refractory epilepsy who are admitted to the Epilepsy Monitoring Unit (EMU) for
      clinically-indicated long-term video-EEG assessment will be simultaneously monitored with
      Sensor Dots to record electroencephalographic (EEG), electrocardiographic (ECG),
      electromyographic (EMG), and motion signals.

      A subset of subjects will continue using Sensor Dot devices at home (Home Phase) after
      completing the EMU Phase.

      The data recorded by Sensor Dots will be used to: 1) annotate epileptic seizures, which will
      be compared to the annotations made as part of routine EMU monitoring and seizure diaries
      kept at home, and 2) to develop seizure detection algorithms. The data collected as part of
      this study will not be used to influence clinical decision making.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of typical absence seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during wakefulness</measure>
    <time_frame>up to two weeks</time_frame>
    <description>F1-score as determined by expert reviewers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of typical absence seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during sleep</measure>
    <time_frame>up to two weeks</time_frame>
    <description>F1-score as determined by expert reviewers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of focal impaired awareness seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during wakefulness</measure>
    <time_frame>up to two weeks</time_frame>
    <description>F1-score as determined by expert reviewers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of focal impaired awareness seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during sleep</measure>
    <time_frame>up to two weeks</time_frame>
    <description>F1-score as determined by expert reviewers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of tonic-clonic seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during wakefulness</measure>
    <time_frame>up to two weeks</time_frame>
    <description>F1-score as determined by expert reviewers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of tonic-clonic seizure annotations derived from Sensor Dot data collected during the EMU Phase against annotations derived from video-EEG equipment during sleep</measure>
    <time_frame>up to two weeks</time_frame>
    <description>F1-score as determined by expert reviewers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensor Dot usability</measure>
    <time_frame>up to two weeks</time_frame>
    <description>We will assess the usability of the device as perceived by users (patients and healthcare personnel) via surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess seizure duration</measure>
    <time_frame>up to two weeks</time_frame>
    <description>From the Sensor Dot data, we will be able to assess seizure duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the usability of the seizure e-diary</measure>
    <time_frame>up to two weeks</time_frame>
    <description>We will asses usability of the electronic seizure diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the accuracy of automated seizure detection algorithms</measure>
    <time_frame>2 years</time_frame>
    <description>We will use the collected data and seizure annotations to develop algorithms to automatically detect epileptic seizures. We plan to evaluate how accurate these new automated seizure detection algorithms are.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of seizure annotations derived from Sensor Dot data collected during the Home Phase against seizure diary annotations</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Accuracy as determined by expert reviewers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensor Dot Performance</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>We will assess the technical performance of the device by comparing the actual length of recorded data against the expected recording length, and what percentage of the data is high quality enough to make seizure annotations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sensor Dot</intervention_name>
    <description>Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects (4+ years old) with refractory epilepsy who are admitted to the hospital for
             clinically-indicated long-term video-EEG assessment or presurgical evaluation, and a
             high likelihood of experiencing seizures during the EMU Phase

          -  For subjects continuing into the Home Phase: successful recording of their habitual
             seizures with Sensor Dot during the EMU Phase

          -  For subjects continuing into the Home Phase: the ability to keep an e-diary

        Exclusion Criteria:

          -  Known allergies to any of the biopotential electrodes or adhesives used as part of the
             study protocol

          -  Having an implanted device, such as (but not limited to) a pacemaker, cardioverter
             defibrillator (ICD), and/or neural stimulation device because Sensor Dot contains
             magnets that could interfere with the operation of these devices

          -  Women who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Van Paesschen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven and KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Broux</last_name>
    <phone>+3216346445</phone>
    <email>victoria.broux@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wim Van Paesschen, MD, PhD</last_name>
    <phone>+3216344332</phone>
    <email>Wim.vanpaesschen@uzleuven.be</email>
  </overall_contact_backup>
  <link>
    <url>https://www.eithealth.eu/seizeit2</url>
    <description>EIT Health website referring to our SeizeIT2 project</description>
  </link>
  <reference>
    <citation>Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14. Review.</citation>
    <PMID>24730690</PMID>
  </reference>
  <reference>
    <citation>Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003 Apr;16(2):165-70. Review.</citation>
    <PMID>12644744</PMID>
  </reference>
  <reference>
    <citation>Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9.</citation>
    <PMID>10660394</PMID>
  </reference>
  <reference>
    <citation>Elger CE, Hoppe C. Diagnostic challenges in epilepsy: seizure under-reporting and seizure detection. Lancet Neurol. 2018 Mar;17(3):279-288. doi: 10.1016/S1474-4422(18)30038-3. Review.</citation>
    <PMID>29452687</PMID>
  </reference>
  <reference>
    <citation>Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol. 2007 Nov;64(11):1595-9.</citation>
    <PMID>17998441</PMID>
  </reference>
  <reference>
    <citation>Kurada AV, Srinivasan T, Hammond S, Ulate-Campos A, Bidwell J. Seizure detection devices for use in antiseizure medication clinical trials: A systematic review. Seizure. 2019 Mar;66:61-69. doi: 10.1016/j.seizure.2019.02.007. Epub 2019 Feb 13.</citation>
    <PMID>30802844</PMID>
  </reference>
  <reference>
    <citation>Bidwell J, Khuwatsamrit T, Askew B, Ehrenberg JA, Helmers S. Seizure reporting technologies for epilepsy treatment: A review of clinical information needs and supporting technologies. Seizure. 2015 Nov;32:109-17. doi: 10.1016/j.seizure.2015.09.006. Epub 2015 Sep 18. Review.</citation>
    <PMID>26552573</PMID>
  </reference>
  <reference>
    <citation>Beniczky S, Ryvlin P. Standards for testing and clinical validation of seizure detection devices. Epilepsia. 2018 Jun;59 Suppl 1:9-13. doi: 10.1111/epi.14049.</citation>
    <PMID>29873827</PMID>
  </reference>
  <reference>
    <citation>Szabó CÁ, Morgan LC, Karkar KM, Leary LD, Lie OV, Girouard M, Cavazos JE. Electromyography-based seizure detector: Preliminary results comparing a generalized tonic-clonic seizure detection algorithm to video-EEG recordings. Epilepsia. 2015 Sep;56(9):1432-7. doi: 10.1111/epi.13083. Epub 2015 Jul 20.</citation>
    <PMID>26190150</PMID>
  </reference>
  <reference>
    <citation>Beniczky S, Conradsen I, Wolf P. Detection of convulsive seizures using surface electromyography. Epilepsia. 2018 Jun;59 Suppl 1:23-29. doi: 10.1111/epi.14048. Review.</citation>
    <PMID>29873829</PMID>
  </reference>
  <reference>
    <citation>Beniczky S, Polster T, Kjaer TW, Hjalgrim H. Detection of generalized tonic-clonic seizures by a wireless wrist accelerometer: a prospective, multicenter study. Epilepsia. 2013 Apr;54(4):e58-61. doi: 10.1111/epi.12120. Epub 2013 Feb 8.</citation>
    <PMID>23398578</PMID>
  </reference>
  <reference>
    <citation>Kjaer TW, Sorensen HBD, Groenborg S, Pedersen CR, Duun-Henriksen J. Detection of Paroxysms in Long-Term, Single-Channel EEG-Monitoring of Patients with Typical Absence Seizures. IEEE J Transl Eng Health Med. 2017 Jan 9;5:2000108. doi: 10.1109/JTEHM.2017.2649491. eCollection 2017.</citation>
    <PMID>29018634</PMID>
  </reference>
  <reference>
    <citation>Zibrandtsen IC, Kidmose P, Christensen CB, Kjaer TW. Ear-EEG detects ictal and interictal abnormalities in focal and generalized epilepsy - A comparison with scalp EEG monitoring. Clin Neurophysiol. 2017 Dec;128(12):2454-2461. doi: 10.1016/j.clinph.2017.09.115. Epub 2017 Oct 12.</citation>
    <PMID>29096220</PMID>
  </reference>
  <reference>
    <citation>Gu Y, Cleeren E, Dan J, Claes K, Van Paesschen W, Van Huffel S, Hunyadi B. Comparison between Scalp EEG and Behind-the-Ear EEG for Development of a Wearable Seizure Detection System for Patients with Focal Epilepsy. Sensors (Basel). 2017 Dec 23;18(1). pii: E29. doi: 10.3390/s18010029.</citation>
    <PMID>29295522</PMID>
  </reference>
  <reference>
    <citation>Dan J, Weckhuysen D, Cleeren E, Van Paesschen W, Vandendriessche B. Technical validation of Sensor Dot: a wearable for ambulatory monitoring of epileptic seizures. 2nd International Congress on mobile devices and seizure detection in epilepsy; Lausanne, Switzerland, 2019.</citation>
  </reference>
  <reference>
    <citation>Seeck M, Koessler L, Bast T, Leijten F, Michel C, Baumgartner C, He B, Beniczky S. The standardized EEG electrode array of the IFCN. Clin Neurophysiol. 2017 Oct;128(10):2070-2077. doi: 10.1016/j.clinph.2017.06.254. Epub 2017 Jul 17. Review.</citation>
    <PMID>28778476</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seizure detection</keyword>
  <keyword>Wearable</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Seizure</keyword>
  <keyword>Sensor Dot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share the individual biosignals (EEG, EMG, ECG and movement) and 24-channel seizure-annotated EEG data, de-identified demographic and epilepsy-related data two years after the finish of the study (1-1-2024) upon request to researchers who provide a methodologically sound proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be shared from 1-1-2024. We do not foresee an end-date.</ipd_time_frame>
    <ipd_access_criteria>Data will be made available upon request to researchers who provide a methodologically sound proposal. Proposals should be directed to Wim.vanpaesschen@uzleuven.be</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

